Leukemia Study
COG #AALL0434 Intensified Methotrexate, Nelarabine (Compound 506U78; IND 52611) and Augmented BFM Therapy for Children and Young Adults with Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia
Protocol ID
Protocol Description
This study will treat patients who have been diagnosed with T-cell acute lymphoblastic leukemia (ALL), a type of cancer that occurs in the bone marrow. The overall goal of this study is to see if we can improve the chances of getting rid of their cancer for as long as possible with acceptable side effects of therapy. Specifically, this study will determine whether a higher dose of methotrexate improves the chances of getting rid of the cancer for as long as possible, with acceptable side effects. This question is being asked because laboratory work has shown that lower doses of methotrexate may not kill T-cell blasts as easily as other kinds of blast cells. In addition, higher doses of methotrexate have been used with success in other treatment plans. Our goal is to see if it improves the chances of getting rid of the cancer for as long as possible with this treatment plan.
Eligibility Criteria
Patients who have been diagnosed with T-cell acute lymphoblastic leukemia (ALL)
Primary Investigator(s)
- Arlene Redner, MD